Close

Anti-SOX9 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2793-CQ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-SOX9 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • SOX9
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 6662
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-2793-CQ CBXS-5445 Rabbit IgG
DMAb-2794-CQ CBXS-5607 Mouse IgG1, κ SOX9 (NP_000337, 400aa-509aa) partial recombinant protein with GST tag
DMAb-2795-CQ CBXS-3856 Mouse IgG1 Purified recombinant fragment of human SOX9
DMAb-2796-CQ CBXS-4642 Mouse IgG1 Human recombinant protein fragment corresponding to amino acids 1-205 of human SOX9 (NP_000337)
DMAb-2797-CQ CBXS-4697 Mouse IgM KLH conjugated synthetic peptide between 41-70 amino acids from human SOX9
DMAb-2798-CQ CBXS-4790 Mouse IgG2a, κ
DMAb-2799-CQ CBXS-4911 Mouse IgG1
DMAb-2800-CQ CBXS-5319 Mouse IgG2a Recombinant protein corresponding to amino acids: SQRTHIKTEQLSPSHYSEQQQHSPQQIAYSPFNLPHYSPSYPPITRSQYDYTDHQNSSSYYSHAAGQGTGLYSTFTYMNPAQRPMYTPIADTSGVPSIPQTHSPQHWEQPVYTQLTR
DMAb-2801-CQ CBXS-0671 Mouse
DMAb-2802-CQ CBXS-1332 Rabbit IgG
DMAb-2803-CQ CBXS-1333 Rabbit IgG
DMAb-2804-CQ CBXS-1376 Rabbit IgG
DMAb-2805-CQ CBXS-1377 Rabbit IgG
DMAb-2806-CQ CBXS-2202 Mouse
DMAb-2807-CQ CBXS-2462 Mouse IgG1 Purified recombinant fragment of human SOX9
DMAb-2808-CQ CBXS-2821 Mouse SOX9 (NP_000337, 400aa-509aa) partial recombinant protein with GST tag
DMAb-2809-CQ CBXS-6157 Mouse IgG1, κ

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-SOX9 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2793-CQ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.